In a preclinical study published in Nature Communications, a team led by Juliana (Hofstatter Azambuja) Yerneni, Ph.D., a researcher in the Department of Laboratory Medicine and Pathology at Mayo Clinic, identified a protein called MALT1 as a critical molecular switch governing this immunological betrayal. MALT1 is an enzyme—a protease—best known for its role in immune cell signaling, where it cleaves other proteins to transmit activation signals in lymphocytes. But the Mayo Clinic team discovered that in the environment of glioblastoma, MALT1’s enzymatic activity plays a far more sinister role: it helps maintain tumor-associated macrophages and other myeloid immune cells in a state that suppresses antitumor immunity rather than promoting it.

Tumor-associated macrophages are among the most abundant immune cells in glioblastoma, and they represent one of the central paradoxes of brain cancer immunology. In theory, macrophages are professional destroyers of abnormal cells, capable of engulfing debris, presenting antigens, and summoning other arms of the immune system to a site of danger. In glioblastoma, however, the tumor co-opts these cells through a barrage of molecular signals, reprogramming them into what researchers often describe as an immunosuppressive state. Instead of rallying an immune assault, they release factors that dampen T cell activity, promote tumor blood vessel formation, and physically construct a protective niche around the cancer. This manipulated microenvironment is a major reason why glioblastoma has proven so resistant to the wave of immunotherapies that have transformed treatment for many other cancers.

The Mayo Clinic team hypothesized that interrupting the signaling pathways that sustain this reprogramming could destabilize the tumor’s protective shield. Their attention settled on MALT1, a protein whose protease activity sits at a critical junction in immune signaling cascades. Using pharmacological inhibitors designed to block MALT1’s enzymatic function, the researchers found that suppressing the protein fundamentally altered the behavior of the immune cells surrounding glioblastoma tumors. Rather than maintaining their tumor-protective, immunosuppressive identity, the macrophages and related myeloid cells shifted toward a state that actively promoted antitumor immune responses. In effect, the guards the tumor had bribed were turned back into soldiers.

The consequences of this reprogramming were striking in preclinical models. When the researchers treated animals bearing glioblastoma with MALT1 inhibitors, tumor growth slowed measurably. The treatment did not merely affect the immune landscape; it translated into tangible control of tumor progression. Encouraged by these results, the team next explored what would happen when MALT1 inhibition was paired with temozolomide, the alkylating chemotherapy that has formed the backbone of glioblastoma treatment since the early 2000s. The logic was compelling: if an immunosuppressive microenvironment blunts the effectiveness of conventional therapy, then dismantling that environment should allow the chemotherapy to do its job more thoroughly.

The combination outperformed expectations. In preclinical models, adding MALT1 inhibition to temozolomide enhanced the chemotherapy’s effectiveness, and in one model, median survival increased substantially compared with treatment using temozolomide alone. For a disease in which median survival with standard care remains measured in months, any substantial extension in a preclinical setting represents a meaningful signal—one that justifies pushing the strategy toward further development.

“Glioblastoma is extraordinarily difficult to treat, in part because the tumor is able to manipulate the immune cells around it and create an environment that protects the cancer,” Yerneni explained in the announcement of the findings. “Our findings point to a potential approach to disrupting that protection and, importantly, to making an existing treatment more effective.”

The clinical stakes could hardly be higher. Glioblastoma accounts for roughly half of all malignant brain tumors in adults and, according to the Mayo Clinic team, represents about 5% of malignant brain tumors in children. Despite decades of effort—aggressive surgery, radiation, and temozolomide-based chemotherapy—the disease remains incurable and almost invariably recurs. Patients diagnosed with glioblastoma face one of the bleakest prognoses in oncology, and the treatment landscape has seen remarkably little meaningful change in nearly two decades. The blood-brain barrier excludes many drugs, the tumor infiltrates healthy brain tissue in finger-like projections that defeat even the most skilled surgeons, and its immunosuppressive microenvironment neutralizes many of the immune-based approaches that have succeeded elsewhere in the body.

Against that grim backdrop, the appeal of the MALT1 strategy lies partly in its simplicity of concept. Rather than attempting to introduce an entirely new therapeutic modality into the brain—a formidable logistics problem given the barriers protecting the central nervous system—the approach seeks to repurpose and amplify the power of a drug that already reaches patients today. Temozolomide is an oral chemotherapy that damages tumor DNA, but its efficacy is limited both by DNA repair mechanisms within tumor cells and by the hostile, immune-suppressed environment that glioblastoma cultivates. By reprogramming the macrophage population around the tumor, MALT1 inhibition appears to address the second of those limitations, creating conditions under which temozolomide’s cytotoxic effects can produce greater clinical benefit.

The work also contributes to a broader and increasingly influential theme in cancer research: the recognition that the tumor microenvironment is not passive scenery but an active participant in disease progression. Over the past two decades, immunotherapy—checkpoint inhibitors, CAR T cells, cancer vaccines—has demonstrated that mobilizing the immune system can produce durable remissions in melanoma, lung cancer, blood cancers, and others. Glioblastoma has stubbornly resisted these advances, in large part because of the myeloid cell-dominated, profoundly immunosuppressive nature of its microenvironment. Strategies that specifically target the mechanisms by which tumors corrupt myeloid cells, rather than merely attempting to stimulate T cells directly, may therefore be better suited to the unique immunology of brain cancer. MALT1 inhibition belongs to this emerging class of approaches.

The research program behind the study is led by senior authors Linda McAllister, M.D., Ph.D., a pediatric oncologist and enterprise deputy director for pediatric cancer programs at the Mayo Clinic Comprehensive Cancer Center, and Peter Lucas, M.D., Ph.D., vice chair for research in the Department of Laboratory Medicine and Pathology. Their laboratory’s overarching mission, as McAllister described it, is to understand how glioblastoma communicates with surrounding immune cells to dampen antitumor immunity, and to translate those discoveries into treatments that strengthen the immune response and improve outcomes for patients with this devastating disease. The fact that the work has relevance for pediatric as well as adult disease adds an additional dimension of urgency, given how limited treatment options are for children with malignant brain tumors.

Importantly, the researchers and their institution are careful to frame the findings as preclinical. Mouse models of glioblastoma, while invaluable, have a notoriously imperfect record at predicting clinical success in humans, and many promising immunotherapies have faltered in translation to brain tumor patients. Several questions remain open. Which molecular subtypes of glioblastoma are most dependent on MALT1-driven myeloid programming, and therefore most likely to respond to the therapy? How would a MALT1 inhibitor behave in the human brain, and what safety considerations arise from targeting a protein that also plays important roles in normal immune cell function? Could long-term suppression of MALT1 compromise the immune system’s ability to fight infection? Answering these questions will require extensive additional research before the strategy can be evaluated in clinical trials.

Even so, the study offers something that glioblastoma research has rarely produced: a mechanism-based way to make an existing therapy meaningfully more effective while simultaneously converting the tumor’s own defenses into vulnerabilities. The idea that flipping the state of a single population of immune cells could slow tumor growth and extend survival—and that doing so could unlock greater benefit from a two-decade-old chemotherapy—captures the kind of elegant biology-meets-therapeutics reasoning that the field has long hoped for. As the Mayo Clinic team continues its work to identify which patients’ tumors are most likely to respond, the findings stand as a reminder that the immune cells surrounding a tumor, once seen as part of the problem, can be reimagined as part of the cure.

For patients and families confronting one of medicine’s most feared diagnoses, such reimagining is not merely an academic exercise. It represents the beginning of a potential path toward treatments that do not simply attack the tumor more aggressively, but intelligently dismantle the shield it has built—and then strike.

News Publication Date: 9-Sep-2026

Web References: https://www.nature.com/articles/s41467-026-76572-7

References: Yerneni, J. H. A., et al. (2026). MALT1 protease inhibition restrains glioblastoma progression by reversing tumor-associated macrophage-dependent immunosuppression in mice. Nature Communications. https://www.nature.com/articles/s41467-026-76572-7

Published recently in Science Translational Medicine, the research delineates the development of a uPAR-specific Chimeric Antigen Receptor (CAR) T cell therapy, an innovative approach that co-opts the patient’s own immune system to target and eradicate glioblastoma cells. Glioblastoma’s intrinsic heterogeneity and invasive nature have historically thwarted effective treatment, culminating in a dismal median survival of less than 15 months post-diagnosis. The introduction of this uPAR-directed therapy offers a beacon of hope for altering this grim prognosis.

At the molecular level, the therapy exploits the expression of the urokinase plasminogen activator receptor (uPAR) on the surface of glioblastoma cells, a protein implicated in tumor proliferation, invasion, and angiogenesis. Notably, uPAR is not confined to malignant cells alone but also adorns adjacent stromal cells which nurture the tumor microenvironment, thus sustaining tumor growth and therapeutic resistance. By generating CAR T cells equipped with antibodies specifically engineered to recognize and bind uPAR, researchers have achieved selective tumor targeting while simultaneously dismantling the tumor-supportive niche, a dual mechanism poised to enhance therapeutic durability and prevent recurrence.

This pioneering immunotherapy was developed through a collaborative endeavor between McMaster University scientists and researchers from Canada’s National Research Council in Ottawa. The synergy of antibody engineering and cellular biology facilitated the creation of CAR constructs with high affinity and specificity for uPAR, enabling potent activation of cytotoxic T cells upon antigen recognition. Preclinical models have showcased not only robust tumor cell killing but also favorable safety profiles, underscoring the therapy’s translational potential.

The innovation signifies a paradigm shift in neuro-oncology, where therapeutic strategies have stagnated for over two decades, constrained by the blood-brain barrier and glioblastoma’s adaptive resistance mechanisms. Sheila Singh, the principal investigator and a renowned professor of surgery and neuro-oncology, emphasizes the urgent need for new treatments and expresses enthusiasm about transitioning this therapy toward clinical application. Her team’s multidisciplinary approach integrates bioengineering, immunology, and clinical neuroscience to overcome glioblastoma’s formidable defenses.

Further augmenting the promise of this research is its alignment with emerging oncology trends that identify uPAR as a universal cancer target beyond glioblastoma. Recent findings from leading institutions, including Memorial Sloan Kettering Cancer Center and Columbia University, corroborate uPAR’s critical role in malignancies such as lung and pancreatic cancers. This convergence propels a broader vision where uPAR-targeted therapies could be tailored to multiple challenging tumor types, amplifying the impact of this discovery.

William Maich, a postdoctoral fellow and first author on the study, reflects on the personal and professional fulfillment derived from this project. His involvement in the adaptive immune response intricacies and patient engagement initiatives highlights a comprehensive approach combining bench science with clinical empathy. The anticipation of providing patients with a new treatment avenue is both motivating and a testament to the translational aspirations driving contemporary cancer research.

Technically, the CAR T cells are bioengineered to express synthetic receptors comprising an extracellular single-chain variable fragment (scFv) derived from uPAR-specific antibodies, linked to intracellular signaling domains that activate T cell effector functions. Upon encountering uPAR-expressing cells, these CAR T cells undergo activation, proliferation, and cytolytic activity, releasing cytotoxins such as perforin and granzymes, resulting in targeted tumor cell apoptosis. Moreover, their ability to recognize stromal elements curtails the supportive matrix that often shelters glioblastoma cells from immune clearance.

Addressing safety concerns critical to CAR T cell therapies, especially in the central nervous system context, the research incorporates safety switches and rigorous off-target assessment protocols. This ensures that therapeutic T cells preferentially attack malignant and microenvironmental support cells without damaging normal brain tissues, mitigating risks of neurotoxicity. Ongoing studies aim to refine these parameters further to optimize clinical outcomes.

Patenting the therapy marks a significant milestone for Singh’s team, paving the path for regulatory discussions and potential commercialization. Collaborative efforts are underway to design and implement early-phase clinical trials, adhering to rigorous standards for first-in-human studies. The objective is to validate efficacy and safety in patients with recurrent glioblastoma, addressing a critical unmet medical need.

As the scientific community rallies around this promising candidate, the broader implications of harnessing immune system precision against refractory brain tumors become increasingly tangible. This research embodies the fusion of molecular innovation, immunotherapy, and translational ambition, potentially setting the stage for a new era in cancer therapeutics where previously incurable diseases might be subdued or eradicated.

In summation, the uPAR-targeted CAR T cell therapy from McMaster University represents a seminal advancement in glioblastoma treatment development. By innovatively targeting a shared oncogenic protein across tumor and stromal cells, this therapeutic approach challenges historical paradigms and offers renewed hope for extended survival and improved quality of life in patients facing this devastating diagnosis. The coming years will be pivotal as the therapy progresses from preclinical validation to the clinical trial landscape, potentially reshaping standards of care in neuro-oncology and beyond.

Subject of Research: Glioblastoma targeted immunotherapy using uPAR-specific CAR T cells

Article Title: uPAR is highly expressed in recurrent glioblastoma and represents a candidate CAR T cell target

News Publication Date: 13-May-2026

Web References:

• Science Translational Medicine DOI: 10.1126/scitranslmed.aea8381

Keywords: Glioblastoma, CAR T cell therapy, uPAR, immunotherapy, brain cancer, neuro-oncology, tumor microenvironment, targeted therapy, molecular oncology, preclinical research, oncology innovation

A major obstacle in treating brain tumors with immunotherapy has been the blood-brain barrier (BBB), a highly selective and protective interface formed by tightly joined endothelial cells. This barrier effectively restricts the penetration of large molecules and immune cells from the bloodstream, safeguarding neural tissue but simultaneously impeding the delivery of anticancer agents and immune cells that could target tumor cells. Even cutting-edge immune checkpoint inhibitors, which unleash the patient’s own T-cell responses against cancer cells, have encountered limited success in high-grade astrocytoma because of this barrier.

Remarkably, researchers at Keck Medicine of USC have pioneered an innovative approach that could redefine the treatment landscape for this devastating disease. By integrating laser interstitial thermal therapy (LITT) with systemic administration of pembrolizumab—an immune checkpoint inhibitor—the team has demonstrated a potential breach in the BBB that enables enhanced immunological targeting of recurrent astrocytoma tumors. This combined modality offers hope for significantly prolonged survival in a patient population that previously had few effective options.

The underlying principle of this approach lies in the dual role of LITT. Traditionally recognized as a minimally invasive technique delivering precise thermal ablation to tumor tissue, LITT not only destroys cancer cells directly but also temporarily disrupts the BBB. The local hyperthermia generated by laser application alters vascular permeability and tight junction integrity for several weeks, creating a transient window during which immune effector cells and systemic immunotherapies can penetrate the tumor microenvironment more effectively.

In a recently published Phase 1/2b clinical trial appearing in Nature Communications, almost half of the patients receiving the LITT-plus-pembrolizumab regimen were alive at 18 months post-treatment, a remarkable improvement over control groups. In stark contrast, none of the patients receiving conventional surgery followed by pembrolizumab survived to the same time point. Even more striking, over one-third of patients undergoing the combination therapy survived beyond three years, dramatically eclipsing the dismal median survival statistics traditionally associated with recurrent high-grade astrocytoma.

Dr. David Tran, MD, PhD, chief of neuro-oncology at Keck Medicine and lead investigator, emphasizes the transformative potential of these findings. He notes that by using LITT to “open the door” through the BBB, pembrolizumab can more effectively rally T-cells to the site of disease. This therapeutic synergy may not only prolong life but also improve quality of life by leveraging the patient’s immune system to maintain tumor control.

The clinical trial design incorporated advanced imaging modalities to guide LITT probe placement with exquisite precision, ensuring maximal tumor ablation while sparing healthy brain regions. Magnetic resonance imaging (MRI) was pivotal in delineating tumor margins and monitoring the extent of BBB disruption. Following ablation, systemic pembrolizumab administration amplified T-cell activation, facilitating immune cell penetration through the temporarily compromised BBB to launch a targeted assault on residual tumor cells.

Patients enrolled in this study predominantly faced advanced disease, many in second or even third recurrence stages, underscoring the severe unmet clinical need. Despite this, the combined therapy exhibited a favorable safety and tolerability profile. Adverse events were manageable and did not preclude therapy continuation, marking an important milestone for the feasibility of this approach in the neuro-oncology treatment paradigm.

This innovative treatment strategy was a collaborative effort across multiple institutions, including Keck Medicine of USC, Washington University in St. Louis, and the University of Florida. The study’s success was bolstered by funding and drug provision from Merck, makers of pembrolizumab, as well as support from Monteris Medical, which supplied the LITT technology. These partnerships highlight the critical need for integrating diagnostic advances, technological innovation, and immunotherapy to overcome the intricate barriers posed by brain tumors.

The implications of this research extend beyond high-grade astrocytoma, opening avenues for combining localized BBB disruption techniques with immunotherapies for other CNS malignancies. It challenges the entrenched understanding that brain tumors are universally impermeable to immune cell infiltration and suggests that transiently breaching this barrier can unleash potent anti-tumor immune responses previously unattainable.

As immune checkpoint inhibition continues to reshape oncology, strategies like LITT-mediated BBB disruption may redefine therapeutic possibilities for brain cancer patients. This approach exemplifies precision medicine by tailoring interventions to the unique physiological challenges of brain tumors, transparently modulating the brain microenvironment to allow immune mechanisms to function optimally.

The study ushers in a new era where neurosurgical innovation and immunology intersect, offering a beacon of hope for patients with high-grade astrocytoma and their families. Future research will be essential to refine timing, dosing, and patient selection to maximize benefits while minimizing risks. Nonetheless, this breakthrough injects momentum into the quest for durable, life-extending treatments in neuro-oncology.

In conclusion, the combined use of laser interstitial thermal therapy and pembrolizumab represents a paradigm shift in managing recurrent high-grade astrocytoma by effectively overcoming the blood-brain barrier. This novel, minimally invasive technique achieves tumor destruction while facilitating immune system access, enhancing the potency of checkpoint blockade against aggressive brain tumors. The data paint a compelling picture of extended survival and improved therapeutic outcomes, marking a critical advance against one of the most lethal forms of brain cancer.

Subject of Research: Treatment of recurrent high-grade astrocytoma/glioblastoma using blood-brain barrier disruption and immunotherapy

Article Title: Breakthrough in Treating Recurrent High-Grade Astrocytoma: Combining Laser-Induced Blood-Brain Barrier Disruption with Immune Checkpoint Inhibition

News Publication Date: Not explicitly stated in the source, but referenced as “published today” alongside the Nature Communications paper

Web References:

• https://www.keckmedicine.org/centers-and-programs/brain-tumor/?gad_source=1&gad_campaignid=20922314521&gbraid=0AAAAAqtYLS3zpwXoH1QGdXUZq4h-O5W7A&gclid=CjwKCAiAv5bMBhAIEiwAqP9GuBOePX1Eal4BCGWsLb52-5UqZzCc7_XWmoi6INEAy70-JrKoJ4WhgBoCDxoQAvD_BwE
• https://www.nature.com/articles/s41467-026-69522-w

References:

• Tran, D.D., et al. (2024). [Title unspecified]. Nature Communications. https://www.nature.com/articles/s41467-026-69522-w

Image Credits: Ricardo Carrasco III

Keywords: Astrocytomas, Brain tumors, Blood-brain barrier, Immune checkpoint inhibitors, Laser interstitial thermal therapy, Immunotherapy, Glioblastoma, Neuro-oncology